What Is a LUL Nodule and What Happens Next?

A LUL nodule is a small spot found in the left upper lobe of your lung, one of five lobes that make up the two lungs. It shows up as a round or oval shadow on a CT scan, and the vast majority of these spots turn out to be harmless. What happens next depends mostly on the nodule’s size, its appearance on imaging, and your personal risk factors for lung cancer. The process can feel unnerving, but the medical playbook for managing lung nodules is well established and designed to avoid unnecessary procedures while catching the rare cases that do need treatment.

What “LUL” Actually Means on Your Report

Your lungs are divided into lobes: three on the right side (upper, middle, and lower) and two on the left (upper and lower). When a radiology report says “LUL nodule,” it is simply telling your doctor where the spot was found. A pulmonary nodule is any small, roughly round opacity in the lung that measures up to about 3 centimeters across. Anything larger than that is typically called a mass rather than a nodule, and masses are handled more urgently.

Upper lobe location does get extra attention in clinical risk models. Several of the scoring systems that doctors use to estimate the chance of cancer treat upper lobe nodules as slightly higher risk than lower lobe ones. This is partly because lung cancers, especially those linked to smoking, tend to appear more frequently in the upper lobes. But “slightly higher risk” still means most upper lobe nodules are benign. The location is just one factor among many that your doctor weighs.

How Common Are Incidental Lung Nodules

Lung nodules are one of the most common surprise findings in medicine. A systematic review pooling data from over 30 studies and roughly 700,000 people found that nodules turn up regularly on chest CT scans done for all sorts of reasons, from heart evaluations to trauma workups.¹ A separate review focused on imaging done for non-cancer reasons confirmed that clinically significant nodules (generally noncalcified ones larger than about 4 to 6 mm) are a frequent incidental discovery, particularly when the scan captures a wide field of view of the chest.²

The sheer number of CT scans performed today means that radiologists and pulmonologists are finding more nodules than ever. The challenge is distinguishing the tiny fraction that represent early-stage lung cancer from the large majority that are completely benign and need no treatment at all.³

What a Nodule Might Be (Besides Cancer)

When people hear “nodule on the lung,” the mind jumps straight to cancer. In reality, benign causes outnumber malignant ones by a wide margin. The most common non-cancerous culprits include:

Granulomas: Small clumps of immune cells that form in response to past infections, especially fungal infections like histoplasmosis or coccidioidomycosis, and mycobacterial infections including tuberculosis. Granulomatous diseases such as sarcoidosis and hypersensitivity pneumonitis can also produce nodules.⁴
Hamartomas: These are the most common benign lung tumors, made of a mix of cartilage, fat, and other normal tissue that grew in the wrong arrangement. A study of 59 hamartoma cases found that over 93% appeared as solitary nodules, spread across all lobes of the lung.⁵
Infections mimicking cancer: Active or healing infections, particularly from fungi and mycobacteria, can create nodules that look worrisome on a scan, sometimes even growing over time or lighting up on PET scans in ways that resemble malignancy.⁶
Lymph nodes and scars: Intrapulmonary lymph nodes and old scar tissue from a previous infection or inflammation can both show up as small nodules.

If you live in or have traveled through regions where certain fungal infections are endemic (much of the Ohio and Mississippi River valleys in the United States, or the desert Southwest), a lung nodule is even more likely to be a harmless remnant of an old infection your immune system already handled.

How Size and Appearance Shape the Plan

The single most important factor in deciding what to do next is the nodule’s size. Tiny nodules, generally those under about 6 mm, carry such a low risk of being cancer that current guidelines often recommend no follow-up at all for patients without significant risk factors.⁷ That is a meaningful shift from older guidelines, which sent more patients back for repeat scans they did not need.

For nodules between roughly 6 and 8 mm, a follow-up CT scan is typically recommended at somewhere around 6 to 12 months, with the exact timing depending on your risk profile. Nodules above 8 mm usually get closer attention, potentially including a PET scan or biopsy.

Appearance matters as much as size. Radiologists look at several features on the CT scan to gauge suspicion:

Solid vs. subsolid: Nodules can be completely solid, entirely ground-glass (hazy, like frosted glass), or part-solid (a mix of both). Part-solid nodules with an irregular internal solid component, lobulated borders, or scattered internal density patterns raise more concern for malignancy.⁸
Shape and edges: Smooth, round nodules with clear borders are more likely benign. Spiculated edges (like the rays of a star), lobulation, and features such as pleural retraction or air bronchograms increase the suspicion of cancer.⁹
Calcification: Certain patterns of calcification (a central “bull’s-eye,” diffuse calcification, or “popcorn” calcification typical of hamartomas) are strong indicators that a nodule is benign. An irregular or eccentric calcification pattern, on the other hand, does not offer the same reassurance.
Stability over time: A nodule that has not changed in size or shape over two or more years of imaging is very unlikely to be cancer. This is one reason surveillance CT scans exist: they are watching for growth.

The Fleischner Society Guidelines

The most widely used framework for managing incidentally discovered lung nodules comes from the Fleischner Society, an international group of radiologists and pulmonologists. Their 2017 updated guidelines simplified earlier versions by combining the recommendations for solid and subsolid nodules into one table and raising the minimum size threshold that triggers follow-up.⁷ The updates also shifted from rigid follow-up schedules to ranges, giving doctors and patients more room to factor in individual circumstances.¹⁰

The guidelines split patients into low-risk and high-risk groups. High-risk generally means a history of smoking or other known risk factors for lung cancer. A low-risk patient with a solid nodule under 6 mm typically needs no follow-up. A high-risk patient with the same nodule might get an optional scan at 12 months. For larger nodules, the intervals tighten and the options expand to include PET scans or tissue sampling. These are the Fleischner guidelines; a separate system called Lung-RADS is used specifically for nodules found during dedicated lung cancer screening programs.¹¹

When a PET Scan Enters the Picture

If a nodule is large enough or suspicious-looking enough, your doctor may order a PET/CT scan. This test uses a radioactive sugar molecule that cancer cells tend to absorb more than normal tissue, making potentially malignant nodules “light up.” The intensity of uptake is measured by a value called SUVmax. A study evaluating PET/CT for solitary pulmonary lesions found that malignant nodules averaged a higher SUVmax, though there is no single cutoff number that perfectly separates cancer from everything else.¹²

PET scans are good but far from perfect. Active infections and inflammatory conditions can also light up, producing false positives. At the same time, slow-growing cancers and very small nodules can fail to light up, producing false negatives. One study of nodules found during lung cancer screening reported that visual analysis of PET/CT achieved about 91% accuracy, with sensitivity of 84% and specificity of 95%.¹³ Raising the SUVmax threshold to improve specificity came at the cost of missing more cancers, so doctors interpret PET results in context rather than relying on a single number. Granulomatous infections are a well-known source of false positives, which is especially relevant if you live in areas where fungal lung infections are common.¹⁴

Biopsy and What It Involves

When imaging alone cannot settle the question, the next step is usually obtaining a tissue sample. The most common approach for peripheral lung nodules is a CT-guided needle biopsy, where a radiologist inserts a thin needle through the chest wall under CT guidance to collect cells from the nodule. This is generally well tolerated, but it does carry a risk of pneumothorax (a partial lung collapse caused by air leaking into the space around the lung). A large meta-analysis covering over 23,000 patients found that about one in four biopsies resulted in some degree of pneumothorax, though only about 7% required a chest tube to fix it.¹⁵ The risk is higher for smaller, deeper nodules and for patients with emphysema.

Alternatives to needle biopsy include bronchoscopy (threading a thin scope through the airways, sometimes with newer navigational or robotic guidance systems) and surgical biopsy. If a nodule is highly suspicious and in a spot that is hard to reach with a needle, a surgeon may opt for a video-assisted thoracoscopic surgery (VATS), a minimally invasive procedure that allows removal of the nodule for both diagnosis and treatment in a single operation.¹⁶ The choice between these approaches depends on the nodule’s size, location, and how suspicious it looks.

If It Turns Out to Be Cancer

For the relatively small percentage of nodules that are malignant, early detection through incidental imaging or screening is the best possible scenario. A nodule-stage lung cancer is typically stage I, meaning it is localized and has not spread. Surgery, often a wedge resection or lobectomy performed through VATS, is the standard treatment, and survival rates for stage I lung cancer are dramatically better than for later stages. The entire reason that nodule surveillance protocols exist is to catch this exact situation: a cancer small enough to be cured.

Occasionally, a lung nodule turns out to be a metastasis from a cancer elsewhere in the body rather than a primary lung cancer. Cancers of the colon, kidney, breast, and skin (melanoma) are among those that commonly spread to the lung. When a patient has a known cancer history, that context changes how the nodule is evaluated. In selected cases, surgical removal of isolated lung metastases can improve survival.¹⁷

The Emotional Weight of Waiting

One of the least discussed but most significant aspects of having a lung nodule is the psychological toll. A multicenter survey found that about a quarter of patients with incidental pulmonary nodules reported clinically significant distress. The top concerns were uncertainty about the nodule’s cause (reported by 78% of respondents), the possibility of cancer (73%), and the potential need for surgery (64%). Only about a quarter of patients accurately estimated their actual risk of lung cancer, and there was essentially no correlation between how risky people thought their nodule was and how risky it actually was.¹⁸

A qualitative study exploring how patients live with indeterminate nodules found that responses evolved over time. Nearly everyone experienced initial fear of cancer, but people eventually sorted into different coping patterns. Most came to accept that the nodule was probably not dangerous. A smaller group remained anxious throughout, convinced the nodule might turn malignant at any moment and wanting aggressive lifelong monitoring. Patients used strategies ranging from information-seeking to deliberate avoidance, and some leaned on faith or focused on controlling modifiable risk factors like smoking.¹⁹ If you are dealing with this, know that the distress is real and common, and that asking your doctor to walk you through your specific risk numbers can actually help. The survey data showed that the minority of patients who received cancer risk information from their provider found it more reassuring than frightening.¹⁸

Artificial Intelligence and Emerging Blood Tests

The tools available for nodule assessment are evolving. Radiomics, which uses computer algorithms to extract patterns from CT images that are invisible to the human eye, is being developed as a supplement to standard risk assessment.²⁰ One example is a tool that generates a risk score based on these hidden image features. When this AI-derived score was added to a traditional clinical prediction model (the Mayo model), predictive accuracy improved and sensitivity at high-risk thresholds rose from 38% to 56%.²¹ The technology is promising but still in its early stages for routine clinical use.

On the blood-test front, researchers are developing assays that detect fragments of tumor DNA circulating in the blood, identified by distinctive chemical markers. A multicenter study of one such test reported an area under the curve of about 0.81 in its validation set, with sensitivity around 74% and specificity around 74%.²² Performance dropped somewhat in the multicenter test set, which is a common pattern when a test is tried across different patient populations. These blood-based tools are not yet ready to replace imaging or biopsy, but they represent a future where some patients might be spared invasive procedures altogether. For now, the standard pathway of serial CT scanning, PET when warranted, and biopsy when needed remains the backbone of nodule management.

Subsolid Nodules and the Long Surveillance Question

Ground-glass and part-solid nodules deserve a separate mention because they follow a different timeline than purely solid ones. These hazy-looking spots can represent pre-malignant conditions or very slow-growing cancers that take years to become a threat. The guidelines call for longer surveillance windows for subsolid nodules, sometimes extending follow-up for several years. A cost-effectiveness analysis found that for high-risk patients, the most economically defensible approach assigned low-risk subsolid nodules a two-year follow-up interval and stopped surveillance after two years for pure ground-glass nodules and after five years for part-solid ones.²³ The risk of overdiagnosis is real with subsolid nodules: some of these spots would never cause symptoms or harm in a patient’s lifetime, yet detecting them triggers a cascade of imaging, worry, and sometimes treatment that the patient did not need. Balancing vigilance against overdiagnosis is one of the ongoing tensions in pulmonary medicine, and it is the reason guidelines keep evolving to be more selective about who gets followed and for how long.

1
PubMed Central. Prevalence and management of pulmonary nodules: a systematic review and meta-analysis
2
PubMed. Prevalence of pulmonary nodules detected incidentally on noncancer-related imaging: a review
3
PubMed Central. Lung nodules: A comprehensive review on current approach and management
4
PubMed Central. Differential diagnosis of granulomatous lung disease: clues and pitfalls
5
PubMed Central. Pulmonary Hamartomas: A Single-Center Analysis of 59 Cases
6
Diagnostic Histopathology. Infections that mimic malignancy in the lung
7
PubMed. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017
8
PubMed Central. Benign and malignant pulmonary part-solid nodules: differentiation via thin-section computed tomography
9
PubMed Central. The differential computed tomography features between small benign and malignant solid solitary pulmonary nodules with different sizes
10
PubMed. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios
11
PubMed. Lung-RADS Version 1.1: Challenges and a Look Ahead
12
Journal of Nuclear Medicine. Accuracy of PET/CT in Characterization of Solitary Pulmonary Lesions
13
PubMed. Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT
14
PubMed Central. Retrospective analysis for the false positive diagnosis of PET-CT scan in lung cancer patients
15
PubMed Central. Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors
16
PubMed. Video-assisted thoracic surgery (VATS) of the lung: analysis of intraoperative and postoperative complications over 15 years and review of the literature
17
ScienceDirect. Secondary pulmonary malignancy
18
PubMed Central. Patients’ Knowledge, Beliefs, and Distress Associated with Detection and Evaluation of Incidental Pulmonary Nodules for Cancer: Results from a Multicenter Survey
19
PubMed Central. ‘The thing is not knowing’: patients’ perspectives on surveillance of an indeterminate pulmonary nodule
20
PubMed Central. Radiomics and artificial intelligence for risk stratification of pulmonary nodules: Ready for primetime?
21
PubMed Central. Clinical utility of an artificial intelligence radiomics-based tool for risk stratification of pulmonary nodules
22
ScienceDirect. Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study
23
ScienceDirect. Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients